{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:30:29Z","timestamp":1787211029806,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23377-1","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:41:06Z","timestamp":1762515666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Paternal valproate use and impact of shared genetic susceptibility on child neurodevelopment"],"prefix":"10.1038","volume":"15","author":[{"given":"Emilie Willoch","family":"Olstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig Marie Egeland","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte-Helene","family":"Bj\u00f8rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Selmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"23377_CR1","doi-asserted-by":"publisher","first-page":"e2519","DOI":"10.1212\/WNL.0000000000010644","volume":"95","author":"J Gesche","year":"2020","unstructured":"Gesche, J., Hjalgrim, H., Rubboli, G. & Beier, C. P. Patterns and prognostic markers for treatment response in generalized epilepsies. Neurology 95, e2519\u2013e2528 (2020).","journal-title":"Neurology"},{"key":"23377_CR2","doi-asserted-by":"publisher","first-page":"106837","DOI":"10.1016\/j.ntt.2019.106837","volume":"76","author":"D Ibi","year":"2019","unstructured":"Ibi, D. et al. Paternal valproic acid exposure in mice triggers behavioral alterations in offspring. Neurotoxicol Teratol. 76, 106837 (2019).","journal-title":"Neurotoxicol Teratol"},{"key":"23377_CR3","doi-asserted-by":"publisher","first-page":"e0282898","DOI":"10.1371\/journal.pone.0282898","volume":"18","author":"K Sakai","year":"2023","unstructured":"Sakai, K., Hara, K. & Tanemura, K. Testicular histone hyperacetylation in mice by valproic acid administration affects the next generation by changes in sperm DNA methylation. PLoS ONE. 18, e0282898 (2023).","journal-title":"PLoS ONE"},{"key":"23377_CR4","unstructured":"Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures | European Medicines Agency (EMA). (2024)."},{"key":"23377_CR5","unstructured":"IQVIA. A Post-Authorisation Safety Study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorders as well as congenital abnormalities in offspring \u2013 a population-based retrospective study. European Medicines Agency (EMA). 2024."},{"key":"23377_CR6","doi-asserted-by":"publisher","first-page":"e2414709","DOI":"10.1001\/jamanetworkopen.2024.14709","volume":"7","author":"J Christensen","year":"2024","unstructured":"Christensen, J., Trabjerg, B. B. & Dreier, J. W. Valproate use during spermatogenesis and risk to offspring. JAMA Netw. Open. 7, e2414709\u2013e2414709 (2024).","journal-title":"JAMA Netw. Open."},{"key":"23377_CR7","doi-asserted-by":"crossref","unstructured":"Honybun, E. et al. Paternal exposure to Antiseizure medications and offspring outcomes: a systematic review. J Neurol. Neurosurg. Psychiatry (2024).","DOI":"10.1136\/jnnp-2024-334077"},{"key":"23377_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0140-6736(12)62129-1","volume":"381","author":"Cross-Disorder Group of the Psychiatric Genomics Consortium","year":"2013","unstructured":"Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371\u20131379 (2013).","journal-title":"Lancet"},{"key":"23377_CR9","unstructured":"Anttila, V. et al. Analysis of shared heritability in common disorders of the brain. Science 360\u00a0(2018)."},{"key":"23377_CR10","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/brain\/awad038","volume":"146","author":"N Karadag","year":"2023","unstructured":"Karadag, N. et al. Identification of novel genomic risk loci shared between common epilepsies and psychiatric disorders. Brain 146, 3392\u20133403 (2023).","journal-title":"Brain"},{"key":"23377_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/ije\/dyl170","volume":"35","author":"P Magnus","year":"2006","unstructured":"Magnus, P. et al. Cohort profile: the Norwegian mother and child cohort study (MoBa). Int. J. Epidemiol. 35, 1146\u20131150 (2006).","journal-title":"Int. J. Epidemiol."},{"key":"23377_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/ije\/dyw029","volume":"45","author":"P Magnus","year":"2016","unstructured":"Magnus, P. et al. Cohort profile update: the Norwegian mother and child cohort study (MoBa). Int. J. Epidemiol. 45, 382\u2013388 (2016).","journal-title":"Int. J. Epidemiol."},{"key":"23377_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10654-006-9041-x","volume":"21","author":"KS R\u00f8nningen","year":"2006","unstructured":"R\u00f8nningen, K. S. et al. The biobank of the Norwegian mother and child cohort study: a resource for the next 100 years. Eur. J. Epidemiol. 21, 619\u2013625 (2006).","journal-title":"Eur. J. Epidemiol."},{"key":"23377_CR14","doi-asserted-by":"crossref","unstructured":"Paltiel, L. et al. The biobank of the Norwegian mother and child cohort Study \u2013 present status. Norsk Epidemiologi 24\u00a0(2014).","DOI":"10.5324\/nje.v24i1-2.1755"},{"key":"23377_CR15","doi-asserted-by":"publisher","first-page":"e70139","DOI":"10.1002\/pds.70139","volume":"34","author":"EW Olstad","year":"2025","unstructured":"Olstad, E. W., Nordeng, H., Bj\u00f8rk, M. H., Selmer, K. K. & Gervin, K. Agreement between parental Self-Reported Antiseizure medication use and dispensed prescription records from a National prescription database. Pharmacoepidemiol Drug Saf. 34, e70139 (2025).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"23377_CR16","doi-asserted-by":"crossref","unstructured":"Corfield, E. C. et al. The Norwegian Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen pipeline v.1. bioRxiv 06.23.496289 (2024). (2022).","DOI":"10.1101\/2022.06.23.496289"},{"key":"23377_CR17","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1093\/bioinformatics\/btaa1029","volume":"36","author":"F Priv\u00e9","year":"2021","unstructured":"Priv\u00e9, F., Arbel, J. & Vilhj\u00e1lmsson, B. J. LDpred2: better, faster, stronger. Bioinformatics 36, 5424\u20135431 (2021).","journal-title":"Bioinformatics"},{"key":"23377_CR18","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.ajhg.2023.10.010","volume":"110","author":"F Priv\u00e9","year":"2023","unstructured":"Priv\u00e9, F., Albi\u00f1ana, C., Arbel, J., Pasaniuc, B. & Vilhj\u00e1lmsson, B. J. Inferring disease architecture and predictive ability with LDpred2-auto. Am. J. Hum. Genet. 110, 2042\u20132055 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"23377_CR19","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41588-023-01485-w","volume":"55","author":"R Stevelink","year":"2023","unstructured":"Stevelink, R. et al. GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. Nat. Genet. 55, 1471\u20131482 (2023).","journal-title":"Nat. Genet."},{"key":"23377_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-022-01285-8","volume":"55","author":"D Demontis","year":"2023","unstructured":"Demontis, D. et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat. Genet. 55, 198\u2013208 (2023).","journal-title":"Nat. Genet."},{"key":"23377_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41588-019-0344-8","volume":"51","author":"J Grove","year":"2019","unstructured":"Grove, J. et al. Identification of common genetic risk variants for autism spectrum disorder. Nat. Genet. 51, 431\u2013444 (2019).","journal-title":"Nat. Genet."},{"key":"23377_CR22","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41596-020-0353-1","volume":"15","author":"SW Choi","year":"2020","unstructured":"Choi, S. W., Mak, T. S. H. & O\u2019Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. Nat. Protoc. 15, 2759\u20132772 (2020).","journal-title":"Nat. Protoc."},{"key":"23377_CR23","doi-asserted-by":"publisher","first-page":"100136","DOI":"10.1016\/j.xhgg.2022.100136","volume":"3","author":"F Priv\u00e9","year":"2022","unstructured":"Priv\u00e9, F., Arbel, J., Aschard, H. & Vilhj\u00e1lmsson, B. J. Identifying and correcting for misspecifications in GWAS summary statistics and polygenic scores. Hum. Genet. Genomics Adv. 3, 100136 (2022).","journal-title":"Hum. Genet. Genomics Adv."},{"key":"23377_CR24","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/bioinformatics\/bty185","volume":"34","author":"F Priv\u00e9","year":"2018","unstructured":"Priv\u00e9, F., Aschard, H., Ziyatdinov, A. & Blum, M. G. B. Efficient analysis of large-scale genome-wide data with two R packages: bigstatsr and Bigsnpr. Bioinformatics 34, 2781\u20132787 (2018).","journal-title":"Bioinformatics"},{"key":"23377_CR25","doi-asserted-by":"crossref","unstructured":"Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res 9 (2020).","DOI":"10.12688\/f1000research.24956.1"},{"key":"23377_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1471-2164-11-293","volume":"11","author":"Y Chen","year":"2010","unstructured":"Chen, Y. et al. Ensembl variation resources. BMC Genom. 11, 293 (2010).","journal-title":"BMC Genom."},{"key":"23377_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS: J. Integr. Biology. 16, 284\u2013287 (2012).","journal-title":"OMICS: J. Integr. Biology"},{"key":"23377_CR28","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov. 2, 100141 (2021).","journal-title":"Innov."},{"key":"23377_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1467-9868.2010.00746.x","volume":"72","author":"Y Benjamini","year":"2010","unstructured":"Benjamini, Y. Discovering the false discovery rate. J. Royal Stat. Society: Ser. B (Statistical Methodology). 72, 405\u2013416 (2010).","journal-title":"J. Royal Stat. Society: Ser. B (Statistical Methodology)"},{"key":"23377_CR30","unstructured":"enrichplot: Visualization of Functional Enrichment Result. R package version 1.24.4. (2024)."},{"key":"23377_CR31","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","volume":"33","author":"JR Conway","year":"2017","unstructured":"Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938\u20132940 (2017).","journal-title":"Bioinformatics"},{"key":"23377_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cell.2018.06.016","volume":"174","author":"AJ Willsey","year":"2018","unstructured":"Willsey, A. J. et al. The psychiatric cell map initiative: A convergent systems biological approach to illuminating key molecular pathways in neuropsychiatric disorders. Cell 174, 505\u2013520 (2018).","journal-title":"Cell"},{"key":"23377_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/ng.2711","volume":"45","author":"SH Lee","year":"2013","unstructured":"Lee, S. H. et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984\u2013994 (2013).","journal-title":"Nat. Genet."},{"key":"23377_CR34","doi-asserted-by":"crossref","unstructured":"Chen, Z., Wang, X., Zhang, S. & Han, F. Neuroplasticity of children in autism spectrum disorder. Front. Psychiatry 15\u00a0(2024).","DOI":"10.3389\/fpsyt.2024.1362288"},{"issue":"Suppl 1","key":"23377_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yebeh.2008.09.023","volume":"14","author":"A Pitk\u00e4nen","year":"2009","unstructured":"Pitk\u00e4nen, A. & Lukasiuk, K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav. 14 (Suppl 1), 16\u201325 (2009).","journal-title":"Epilepsy Behav."},{"key":"23377_CR36","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2019.11.020","volume":"179","author":"Genomic","year":"2019","unstructured":"Genomic & Relationships Novel Loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 179, 1469\u20131482e11 (2019).","journal-title":"Cell"},{"key":"23377_CR37","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1038\/s41467-024-50295-z","volume":"15","author":"HO Heyne","year":"2024","unstructured":"Heyne, H. O. et al. Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events. Nat. Comms. 15, 6277 (2024).","journal-title":"Nat. Comms"},{"key":"23377_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/jnnp-2020-323028","volume":"91","author":"T Tomson","year":"2020","unstructured":"Tomson, T., Muraca, G. & Razaz, N. Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden. J. Neurol. Neurosurg. Psychiatry. 91, 907 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"23377_CR39","doi-asserted-by":"publisher","first-page":"1094698","DOI":"10.3389\/fphar.2023.1094698","volume":"14","author":"RL Bromley","year":"2023","unstructured":"Bromley, R. L. et al. Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies. Front. Pharmacol. 14, 1094698 (2023).","journal-title":"Front. Pharmacol."},{"key":"23377_CR40","doi-asserted-by":"crossref","unstructured":"Bishop, D. & Rutter, M. in Rutter\u2019s Child and Adolescent Psychiatry, 32\u201341 (2008).","DOI":"10.1002\/9781444300895.ch3"},{"key":"23377_CR41","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(15)00238-X","volume":"387","author":"A Thapar","year":"2016","unstructured":"Thapar, A. & Cooper, M. Attention deficit hyperactivity disorder. Lancet 387, 1240\u20131250 (2016).","journal-title":"Lancet"},{"key":"23377_CR42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0140-6736(18)31129-2","volume":"392","author":"C Lord","year":"2018","unstructured":"Lord, C., Elsabbagh, M., Baird, G. & Veenstra-Vanderweele, J. Autism spectrum disorder. Lancet 392, 508\u2013520 (2018).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23377-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23377-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23377-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:41:10Z","timestamp":1762515670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23377-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23377"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23377-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MHB reports advisory board honoraria or\/and speaking honoraria from Pfizer, Jazz Pharmaceuticus, Angelini Pharma, AbbVie, Lundbeck and Eisai. Received biostatistical research support from Novartis unrelated to the present study; her department has received funding from valproate marked authorization holders to conduct postmarketing drug safety research outside the submitted work, and she is PI on an industry financed phase IV study of a migraine preventive drug (eptinezumab) unrelated to the drugs studied in the present work. KS has received consultant and speaker\u2019s honoraria from Roche and OrionPharma. She also received non\u2010personal sponsorships from Desitin and Eisai AB in relation to organizing conferences. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39033"}}